Search results
Showing 106 to 120 of 123 results for nivolumab
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Awaiting development [GID-TA11586] Expected publication date: TBC
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued [GID-TA10970]
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
This guidance has been updated and replaced by NICE technology appraisal guidance 780.
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued [GID-TA11421]
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
In development [GID-TA11010] Expected publication date: TBC
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655.
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development [GID-TA10935] Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
This guidance has been updated and replaced by NICE technology appraisal guidance 713.
In development [GID-TA10826] Expected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
In development [GID-TA11253] Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 736.